InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,229.20
(
-0.15%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
-0.72%
)
Bitcoin
64,074.37
(
-1.19%
)
Post# of 252300
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 246689

Wednesday, 05/31/2023 6:32:08 PM

Wednesday, May 31, 2023 6:32:08 PM

Post# of 252300
FDA approves Abrysvo—(PFE’s RSV vaccine)—for adults 60+:

https://www.businesswire.com/news/home/20230530005660/en

Today was the PDUFA date.

GSK’s similar RSV vaccine, Arexvy, was approved for adults 60+ by the FDA four weeks ago (#msg-171831470).

PFE’s separate BLA for its maternal RSV vaccine—to protect newborns for up to six months—has a PDUFA date in August 2023 (#msg-171260623) and was recently endorsed by VRBPAC (#msg-171942839). PFE is the only company with such a vaccine, as far as I know.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up